Iberdomide

Iberdomide
Identifiers
	IUPAC name (3S)-3-[7-[[4-(Morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;
CAS Number	1323403-33-3;
PubChem CID	67335295;
IUPHAR/BPS	9618;
DrugBank	DB12101;
ChemSpider	52085251;
UNII	8V66F27X44;
KEGG	D11134;
ChEMBL	ChEMBL3989927;
Chemical and physical data
Formula	C25H27N3O5
Molar mass	449.507 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5;
	InChI InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1; Key:IXZOHGPZAQLIBH-NRFANRHFSA-N;

Iberdomide (CC-220) is an experimental thalidomide analog that works as an cereblon E3 ligase modulator; it has a higher binding affinity than lenalidomide or pomalidomide. It is developed by Bristol Myers Squibb for various cancers and was also tested in people with lupus.

Iberdomide has been tested in combination with Bi-specific T-cell engagers in the B-Cell Non-Hodgkin Lymphoma setting, but has been dropped in favor of Golcadomide (CC-99282).

Identifiers

IUPAC name (3S)-3-[7-[[4-(Morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione
CAS Number	1323403-33-3
PubChem CID	67335295
IUPHAR/BPS	9618
DrugBank	DB12101
ChemSpider	52085251
UNII	8V66F27X44
KEGG	D11134
ChEMBL	ChEMBL3989927
Chemical and physical data
Formula	C₂₅H₂₇N₃O₅
Molar mass	449.507 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5
InChI InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1 Key:IXZOHGPZAQLIBH-NRFANRHFSA-N